Foundry Healthcare Sales-to-Price Factor ETF
ETF Foundry Research (hypothetical) · rebalanced monthly
Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.
Hypothetical growth of $1 — long-short backtest
Gross of the placeholder expense ratio and trading costs · not investor results
Holdings
Every constituent of the long leg — sort, search or filter by sector
| Ticker | Company | Sector | Market cap | Weight |
|---|---|---|---|---|
1UNH | UNITEDHEALTH GROUP INC | Healthcare | $386.95B | 28.65% |
2CVS | CVS HEALTH CORP | Healthcare | $137.12B | 10.15% |
3MCK | MCKESSON CORP | Healthcare | $101.14B | 7.49% |
4HCA | HCA HEALTHCARE INC | Healthcare | $82.34B | 6.10% |
5ELV | ELEVANCE HEALTH INC | Healthcare | $80.92B | 5.99% |
6CI | CIGNA GROUP | Healthcare | $74.45B | 5.51% |
7COR | CENCORA INC | Healthcare | $59.91B | 4.44% |
8CAH | CARDINAL HEALTH INC | Healthcare | $53.52B | 3.96% |
9HUM | HUMANA INC | Healthcare | $48.02B | 3.56% |
10CNC | CENTENE CORP | Healthcare | $32.81B | 2.43% |
11GEHC | GE HEALTHCARE TECHNOLOGIES INC | Healthcare | $28.69B | 2.12% |
12LH | LABCORP HOLDINGS INC | Healthcare | $23.24B | 1.72% |
13VTRS | VIATRIS INC | Healthcare | $20.14B | 1.49% |
14THC | TENET HEALTHCARE CORP | Healthcare | $16.79B | 1.24% |
15DVA | DAVITA INC | Healthcare | $15.21B | 1.13% |
16SOLV | SOLVENTUM CORP | Healthcare | $14.08B | 1.04% |
17BTSG | BRIGHTSPRING HEALTH SERVICES INC | Healthcare | $13.71B | 1.02% |
18MOH | MOLINA HEALTHCARE INC | Healthcare | $11.74B | 0.87% |
19BAX | BAXTER INTERNATIONAL INC | Healthcare | $11.68B | 0.86% |
20HSIC | HENRY SCHEIN INC | Healthcare | $10.00B | 0.74% |
21UHS | UNIVERSAL HEALTH SERVICES INC | Healthcare | $9.15B | 0.68% |
22OSCR | OSCAR HEALTH INC | Healthcare | $8.77B | 0.65% |
23PACS | PACS GROUP INC | Healthcare | $7.30B | 0.54% |
24BLCO | BAUSCH & LOMB CORP | Healthcare | $5.80B | 0.43% |
25MMED | MINIMED GROUP INC | Healthcare | $4.75B | 0.35% |
26NVST | ENVISTA HOLDINGS CORP | Healthcare | $4.35B | 0.32% |
27ALHC | ALIGNMENT HEALTHCARE INC | Healthcare | $4.26B | 0.32% |
28BKD | BROOKDALE SENIOR LIVING INC | Healthcare | $3.58B | 0.27% |
29OGN | ORGANON & CO | Healthcare | $3.55B | 0.26% |
30OPCH | OPTION CARE HEALTH INC | Healthcare | $3.41B | 0.25% |
31PRVA | PRIVIA HEALTH GROUP INC | Healthcare | $3.39B | 0.25% |
32ITGR | INTEGER HOLDINGS CORP | Healthcare | $3.24B | 0.24% |
33ACHC | ACADIA HEALTHCARE COMPANY INC | Healthcare | $3.17B | 0.23% |
34XRAY | DENTSPLY SIRONA INC | Healthcare | $2.81B | 0.21% |
35GRDN | GUARDIAN PHARMACY SERVICES INC | Healthcare | $2.57B | 0.19% |
36ASTH | ASTRANA HEALTH INC | Healthcare | $2.50B | 0.19% |
37AGL | AGILON HEALTH INC | Healthcare | $2.17B | 0.16% |
38MD | PEDIATRIX MEDICAL GROUP INC | Healthcare | $2.15B | 0.16% |
39ADUS | ADDUS HOMECARE CORP | Healthcare | $2.14B | 0.16% |
40AVAH | AVEANNA HEALTHCARE HOLDINGS INC | Healthcare | $2.11B | 0.16% |
41SGRY | SURGERY PARTNERS INC | Healthcare | $2.09B | 0.15% |
42OMCL | OMNICELL INC | Healthcare | $2.09B | 0.15% |
43SRPT | SAREPTA THERAPEUTICS INC | Healthcare | $1.82B | 0.13% |
44HCSG | HEALTHCARE SERVICES GROUP INC | Healthcare | $1.74B | 0.13% |
45TDOC | TELADOC HEALTH INC | Healthcare | $1.70B | 0.13% |
46FTRE | FORTREA HOLDINGS INC | Healthcare | $1.68B | 0.12% |
47INNV | INNOVAGE HOLDING CORP | Healthcare | $1.56B | 0.12% |
48IART | INTEGRA LIFESCIENCES HOLDINGS CORP | Healthcare | $1.50B | 0.11% |
49AHCO | ADAPTHEALTH CORP | Healthcare | $1.49B | 0.11% |
50PRGO | PERRIGO CO PLC | Healthcare | $1.48B | 0.11% |
51PNTG | PENNANT GROUP INC | Healthcare | $1.46B | 0.11% |
52INSP | INSPIRE MEDICAL SYSTEMS INC | Healthcare | $1.46B | 0.11% |
53ARDT | ARDENT HEALTH INC | Healthcare | $1.46B | 0.11% |
54AMN | AMN HEALTHCARE SERVICES INC | Healthcare | $1.36B | 0.10% |
55PAHC | PHIBRO ANIMAL HEALTH CORP | Healthcare | $1.35B | 0.10% |
56ATEC | ALPHATEC HOLDINGS INC | Healthcare | $1.31B | 0.10% |
57CNMD | CONMED CORP | Healthcare | $1.30B | 0.10% |
58QDEL | QUIDELORTHO CORP | Healthcare | $1.19B | 0.09% |
59TNDM | TANDEM DIABETES CARE INC | Healthcare | $1.17B | 0.09% |
60COLL | COLLEGIUM PHARMACEUTICAL INC | Healthcare | $1.17B | 0.09% |
61AVNS | AVANOS MEDICAL INC | Healthcare | $1.17B | 0.09% |
62NUTX | NUTEX HEALTH INC | Healthcare | $1.12B | 0.08% |
63USPH | U S PHYSICAL THERAPY INC | Healthcare | $1.12B | 0.08% |
64PCRX | PACIRA BIOSCIENCES INC | Healthcare | $1.01B | 0.07% |
65BVS | BIOVENTUS INC | Healthcare | $1.01B | 0.07% |
66AMPH | AMPHASTAR PHARMACEUTICALS INC | Healthcare | $871M | 0.06% |
67PHR | PHREESIA INC | Healthcare | $662M | 0.05% |
68CRMD | CORMEDIX INC | Healthcare | $661M | 0.05% |
69EVH | EVOLENT HEALTH INC | Healthcare | $654M | 0.05% |
70MYGN | MYRIAD GENETICS INC | Healthcare | $584M | 0.04% |
71FLGT | FULGENT GENETICS INC | Healthcare | $573M | 0.04% |
72ANGO | ANGIODYNAMICS INC | Healthcare | $558M | 0.04% |
73TOI | ONCOLOGY INSTITUTE INC | Healthcare | $535M | 0.04% |
74CTEV | CLARITEV CORP | Healthcare | $518M | 0.04% |
75OFIX | ORTHOFIX MEDICAL INC | Healthcare | $468M | 0.03% |
76VMD | VIEMED HEALTHCARE INC | Healthcare | $466M | 0.03% |
77VREX | VAREX IMAGING CORP | Healthcare | $444M | 0.03% |
78CCRN | CROSS COUNTRY HEALTHCARE INC | Healthcare | $428M | 0.03% |
79EBS | EMERGENT BIOSOLUTIONS INC | Healthcare | $394M | 0.03% |
80TBRG | TRUBRIDGE INC | Healthcare | $394M | 0.03% |
81EOLS | EVOLUS INC | Healthcare | $377M | 0.03% |
82VNDA | VANDA PHARMACEUTICALS INC | Healthcare | $327M | 0.02% |
83SPOK | SPOK HOLDINGS INC | Healthcare | $222M | 0.02% |
84KPTI | KARYOPHARM THERAPEUTICS INC | Healthcare | $216M | 0.02% |
85AGEN | AGENUS INC | Healthcare | $209M | 0.02% |
86ANIK | ANIKA THERAPEUTICS INC | Healthcare | $203M | 0.02% |
87AMWL | AMERICAN WELL CORP | Healthcare | $199M | 0.01% |
88INFU | INFUSYSTEM HOLDINGS INC | Healthcare | $180M | 0.01% |
89INGN | INOGEN INC | Healthcare | $178M | 0.01% |
90OWLT | OWLET INC | Healthcare | $162M | 0.01% |
91OPRX | OPTIMIZERX CORP | Healthcare | $126M | 0.01% |
92CSBR | CHAMPIONS ONCOLOGY INC | Healthcare | $85M | 0.01% |
93PIII | P3 HEALTH PARTNERS INC | Healthcare | $78M | 0.01% |
94LNSR | LENSAR INC | Healthcare | $70M | 0.01% |
95SNWV | SANUWAVE HEALTH INC | Healthcare | $55M | 0.00% |
96XLO | XILIO THERAPEUTICS INC | Healthcare | $53M | 0.00% |
Full long-leg book as of July 2026 · cap-weighted · total market cap $1.35T. Hypothetical model holdings — not a registered fund’s portfolio.
Sector Breakdown
Portfolio Style
Size × value map of the long-leg book
Share of long-leg capital by market cap × book-to-market, using terciles of the 499-name universe at July 2026. Rows: Large ≥ $3.6B, Small < $964M. Columns: Value ≥ 0.67, Growth < 0.37 B/M. The dot marks the capital-weighted centroid of the book — 97% toward Large, 41% toward Growth. +4% unclassified (20 missing size/value). Hypothetical holdings — descriptive, not realized P&L.
Capital-weighted centroid of the long leg, December 1998 → July 2026; the right-hand end is the same value as the box’s dot. 96 names now. The faded start covers early months with a much thinner universe. Hypothetical holdings — descriptive, not P&L.
Constraint checks
How this book measures against the concentration and liquidity rules — as implemented here
These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.
7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.
1 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.
With respect to 75% of total assets, no more than 5% may be invested in the securities of any one issuer.
Required>= 75.0%Actual66.1%Margin-8.9%No more than 25% of total assets may be invested in the securities of any one issuer.
Required<= 25.0%Actual28.7%Margin-3.7%
Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.
No verdict sits within 1.0pp of its limit.
Data version — panel=20260719T025334 rows=2239262 asof=202607 issuers=20260719T014536 rates=20260804T224700
Measured on the 2026-07 formation date across 96 holdings (cap-weighted). A different formation date can produce different verdicts.
Derivatives risk (Rule 18f-4)
Whether this long-only book is subject to the VaR tests at all
This assessment describes the long-only book this fund holds — the top bucket only.
This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.
Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.
No confidence interval: this follows from portfolio construction, not from an estimate.
Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.
Informational — does not governThis fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.
historical method · 331 monthly observations · about 3.3 in the 99% tail · paired percentile bootstrap over months
The estimators differ materially in value but agree on the verdict. Historical and Gaussian fund VaR differ by 27%; both still land on the same side of the 2x limit.
Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.
The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.
See the long-short verdict on the factor page →Since publication
Did the edge survive the paper coming out?
There is no “before” to compare against — the predictor was already public when our data begins, so every month shown is out-of-sample relative to the original study.
Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.
Consistency across eras
Is this record broadly durable, or one regime?
3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.
Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.
Returns
Long leg is what this fund holds — long-short is shown for reference
| Period | Long leg | Long-short |
|---|---|---|
| 1 yearcum. | 46.5% | -31.5% |
| 3 yearsp.a. | 5.3% | -23.0% |
| 5 yearsp.a. | 5.6% | -6.3% |
| 10 yearsp.a. | 9.9% | -4.8% |
| Since inceptionp.a. | 12.3% | -3.6% |
| Year | Long leg | Long-short |
|---|---|---|
| 20267 mo | 17.2% | -16.5% |
| 2025 | 1.8% | -28.4% |
| 2024 | -5.4% | -6.3% |
| 2023 | 2.3% | -27.2% |
| 2022 | 3.3% | 32.6% |
| 2021 | 31.0% | 106.9% |
| 2020 | 13.1% | -25.0% |
| 2019 | 20.4% | -23.2% |
| 2018 | 4.0% | 26.4% |
| 2017 | 20.5% | -26.6% |
| 2016 | -0.5% | 26.8% |
| 2015 | 8.4% | 3.6% |
| 2014 | 31.0% | -12.7% |
| 2013 | 47.3% | 0.8% |
| 2012 | 14.3% | -14.3% |
| 2011 | 14.6% | 11.2% |
| 2010 | 14.0% | 4.2% |
| 2009 | 31.6% | 12.9% |
| 2008 | -43.2% | -31.5% |
| 2007 | 17.6% | 20.9% |
| 2006 | 5.1% | 13.2% |
| 2005 | 30.9% | 8.7% |
| 2004 | 22.0% | 24.2% |
| 2003 | 35.8% | -6.8% |
| 2002 | -5.8% | 80.6% |
| 2001 | -1.5% | 14.5% |
| 2000 | 76.0% | -59.9% |
| 1999 | -10.2% | -52.5% |
Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through July 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.
Fund Facts
Methodology
The Foundry Healthcare Sales-to-Price Factor ETF tracks a rules-based model that ranks Healthcare common stocks each month by a Sales-to-Price signal and holds the top quintile with the highest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.
This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.
Documents (draft — hypothetical)
Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.
Objective, fees, strategy, and key risks.
Full strategy, model methodology, and risks.
Policies, construction, and governance.
One-page snapshot with top holdings.
Full current constituent list.
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.